IMU

3.53%

8.2¢ imugene limited

"Another good possibility is a partnership with BP, allowing...

First 21164 Last

Share
Profile

Follow
SENARIS

2,919 Posts.

132

03/02/24

17:38

Post #: 72221996
Share

"Another good possibility is a partnership with BP, allowing Imugene to further develop their technologies with the financial support of a big player"

IMO this is exactly what IMU need so as to pay for all the wages and costs of the new Azer Cell facility and the wage costs associated with all the recent job adverts for the various roles.

And off course, the financial support will assist with ongoing costs of running the trials and progressing the IP.

This scenario of financial support would ensure (you'd think) any further CR or at least limited CR.

The SP would catapult to 50c in an instance !

Originally posted by Hawkbar33: ↑

There will be no approvals in 2024, we are looking at possibly a Registrational trial fro azer-cel and possibly accelerated approval for Vaccinia in 2025.
The big game will be a deal or licencing of one or both of these products which again may or may not come in 2024.
Another good possibility is a partnership with BP, allowing Imugene to further develop their technologies with the financial support of a big player, which has been mentioned by others as possibly being Genetech Roche.
We know they are looking, we know there are synogies between the companies including person to person relationships.
One thing is for certain, everything that Leslie and Yuman have said is playing out from a scientific perspective and as the next 12 months plays out all will come together beautifully.
Good luck to all investors who have been on this journey, especially those who early on saw the promise in this company and of course my thought to those that have taken the risk, dare I say gamble to go onto trials that offer no promise just the hope that their treatment may give them a few precious months more with their families.

DYOR opinion only

Expand

Originally posted by Hawkbar33: ↑

There will be no approvals in 2024, we are looking at possibly a Registrational trial fro azer-cel and possibly accelerated approval for Vaccinia in 2025.
The big game will be a deal or licencing of one or both of these products which again may or may not come in 2024.
Another good possibility is a partnership with BP, allowing Imugene to further develop their technologies with the financial support of a big player, which has been mentioned by others as possibly being Genetech Roche.
We know they are looking, we know there are synogies between the companies including person to person relationships.
One thing is for certain, everything that Leslie and Yuman have said is playing out from a scientific perspective and as the next 12 months plays out all will come together beautifully.
Good luck to all investors who have been on this journey, especially those who early on saw the promise in this company and of course my thought to those that have taken the risk, dare I say gamble to go onto trials that offer no promise just the hope that their treatment may give them a few precious months more with their families.

DYOR opinion only

Expand

IMU Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 1,942 more messages in this thread...

First 21164 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 8.2¢		Change -0.003(3.53%)		Mkt cap ! $600.2M

Open	High	Low	Value	Volume
8.5¢	8.6¢	8.2¢	$1.246M	14.84M

Buyers (Bids)

No.	Vol.	Price($)
4	446526	8.2¢

Sellers (Offers)

Price($)	Vol.	No.
8.3¢	535664	2

View Market Depth

No.	Vol.	Price($)
2	246526	0.082
14	789971	0.081
13	589034	0.080
13	1492987	0.079
10	965909	0.078

Price($)	Vol.	No.
0.083	35664	1
0.084	759220	3
0.085	752325	5
0.086	1094041	7
0.087	1140229	4

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last 8.2¢		Change -0.003 ( 2.38 %)
Open	High	Low	Volume
8.6¢	8.6¢	8.2¢	4518456
Last updated 15.57pm 03/05/2024 ?

IMU (ASX) Chart

"Another good possibility is a partnership with BP, allowing...

Featured News

Dancing to that same 70s tune, China, and why I'm backing gold

Infini Resources gearing up for UAV geophys survey over Portland Creek

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Car EV-olution accelerates Oz into pole position

BPH Energy renews NT Bonaparte Basin permit

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

Provident Aurum's off-market bid sends Sihayo shares soaring

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Buyers (Bids)

Sellers (Offers)

Featured News

"Another good possibility is a partnership with BP, allowing...

Featured News

Top Stories

Dancing to that same 70s tune, China, and why I'm backing gold

Infini Resources gearing up for UAV geophys survey over Portland Creek

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Car EV-olution accelerates Oz into pole position

BPH Energy renews NT Bonaparte Basin permit

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

Provident Aurum's off-market bid sends Sihayo shares soaring

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Buyers (Bids)

Sellers (Offers)

Featured News